Shire Finally Gets Resuscitated Adult ADHD Drug Back On Track With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The 16-hour ADHD candidate SHP465 (SPD465) is being aimed at adults, but FDA wants a study in children, which will kick off in August and may allow a launch by the end of 2017, Shire says.
You may also be interested in...
Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)
Flemming Ornskov says FDA approval of long-lasting ADHD therapy Mydayis is part of Shire's plan to dramatically increase neuroscience revenues – but it won't launch the drug outside the US for some time.
Shire Targets SHP465 ADHD Resubmission 10 Years After Initial Filing
Shire says it is on track to refile its long-shelved ADHD candidate SHP465 later this year after a Phase III trial in children and adolescents turned out positively.
Shire Receives FDA “Approvable” Letter On Adult Adderall Product
With an adult filing for Adderall replacement Vyvanse set for mid year, the company is weighing its options, Shire told “The Pink Sheet” DAILY.